Neuropsychiatric systemic lupus erythematosus: Pathophysiology and the future of treatment

Takahisa Gono, Takeshi Takarada, Yasuhiro Katsumata, Yasushi Kawaguchi, Yukio Yoneda, Hisashi Yamanaka

Research output: Contribution to journalReview article

Abstract

Systemic lupus erythematosus (SLE) is characterized by the presence of several autoantibodies, including anti-dsDNA. Among types of SLE, neuropsychiatric (NP)-SLE accounts for significant morbidity and mortality. Cerebrovascular disease, which could account for most of the serious permanent neurological damage, is a common presentation of NP-SLE. The pathophysiology of NP-SLE involves several factors, including vasculitis, thrombosis, and inflammation and/or apoptosis of neuronal and glial cells. The current treatment strategy is immunosuppressive therapy, which is occasionally insufficient for patients with NP-SLE. Recent studies have revealed that autoantibodies, such as anti-NR2, pass from the peripheral blood to the brain through the blood-brain barrier, cross-react with human brain tissue and cause increased intracellular Ca2+ in SLE. Regulating blood-brain barrier permeability, inhibiting autoantibody deposition in tissues and modulating intracellular Ca2+ may be new concepts for the treatment with NP-SLE.

Original languageEnglish
Pages (from-to)585-595
Number of pages11
JournalInternational Journal of Clinical Rheumatology
Volume8
Issue number5
DOIs
Publication statusPublished - Oct 2013
Externally publishedYes

Fingerprint

Central Nervous System Lupus Vasculitis
Systemic Lupus Erythematosus
Autoantibodies
Blood-Brain Barrier
Therapeutics
Cerebrovascular Disorders
Brain
Immunosuppressive Agents
Vasculitis
Neuroglia
Permeability
Thrombosis
Apoptosis
Inflammation
Morbidity
Mortality

Keywords

  • anti-NR2
  • antiphospholipid
  • antiribosomal P
  • autoantibodies
  • blood-brain barrier permeability
  • cross-reactivity
  • intracellular Ca signaling
  • neuropsychiatric symptoms
  • systemic lupus erythematosus

ASJC Scopus subject areas

  • Rheumatology

Cite this

Neuropsychiatric systemic lupus erythematosus : Pathophysiology and the future of treatment. / Gono, Takahisa; Takarada, Takeshi; Katsumata, Yasuhiro; Kawaguchi, Yasushi; Yoneda, Yukio; Yamanaka, Hisashi.

In: International Journal of Clinical Rheumatology, Vol. 8, No. 5, 10.2013, p. 585-595.

Research output: Contribution to journalReview article

Gono, Takahisa ; Takarada, Takeshi ; Katsumata, Yasuhiro ; Kawaguchi, Yasushi ; Yoneda, Yukio ; Yamanaka, Hisashi. / Neuropsychiatric systemic lupus erythematosus : Pathophysiology and the future of treatment. In: International Journal of Clinical Rheumatology. 2013 ; Vol. 8, No. 5. pp. 585-595.
@article{e1845f2b21224d4cac1090e5d8a6c8ac,
title = "Neuropsychiatric systemic lupus erythematosus: Pathophysiology and the future of treatment",
abstract = "Systemic lupus erythematosus (SLE) is characterized by the presence of several autoantibodies, including anti-dsDNA. Among types of SLE, neuropsychiatric (NP)-SLE accounts for significant morbidity and mortality. Cerebrovascular disease, which could account for most of the serious permanent neurological damage, is a common presentation of NP-SLE. The pathophysiology of NP-SLE involves several factors, including vasculitis, thrombosis, and inflammation and/or apoptosis of neuronal and glial cells. The current treatment strategy is immunosuppressive therapy, which is occasionally insufficient for patients with NP-SLE. Recent studies have revealed that autoantibodies, such as anti-NR2, pass from the peripheral blood to the brain through the blood-brain barrier, cross-react with human brain tissue and cause increased intracellular Ca2+ in SLE. Regulating blood-brain barrier permeability, inhibiting autoantibody deposition in tissues and modulating intracellular Ca2+ may be new concepts for the treatment with NP-SLE.",
keywords = "anti-NR2, antiphospholipid, antiribosomal P, autoantibodies, blood-brain barrier permeability, cross-reactivity, intracellular Ca signaling, neuropsychiatric symptoms, systemic lupus erythematosus",
author = "Takahisa Gono and Takeshi Takarada and Yasuhiro Katsumata and Yasushi Kawaguchi and Yukio Yoneda and Hisashi Yamanaka",
year = "2013",
month = "10",
doi = "10.2217/ijr.13.48",
language = "English",
volume = "8",
pages = "585--595",
journal = "Future Rheumatology",
issn = "1758-4272",
publisher = "Future Medicine Ltd.",
number = "5",

}

TY - JOUR

T1 - Neuropsychiatric systemic lupus erythematosus

T2 - Pathophysiology and the future of treatment

AU - Gono, Takahisa

AU - Takarada, Takeshi

AU - Katsumata, Yasuhiro

AU - Kawaguchi, Yasushi

AU - Yoneda, Yukio

AU - Yamanaka, Hisashi

PY - 2013/10

Y1 - 2013/10

N2 - Systemic lupus erythematosus (SLE) is characterized by the presence of several autoantibodies, including anti-dsDNA. Among types of SLE, neuropsychiatric (NP)-SLE accounts for significant morbidity and mortality. Cerebrovascular disease, which could account for most of the serious permanent neurological damage, is a common presentation of NP-SLE. The pathophysiology of NP-SLE involves several factors, including vasculitis, thrombosis, and inflammation and/or apoptosis of neuronal and glial cells. The current treatment strategy is immunosuppressive therapy, which is occasionally insufficient for patients with NP-SLE. Recent studies have revealed that autoantibodies, such as anti-NR2, pass from the peripheral blood to the brain through the blood-brain barrier, cross-react with human brain tissue and cause increased intracellular Ca2+ in SLE. Regulating blood-brain barrier permeability, inhibiting autoantibody deposition in tissues and modulating intracellular Ca2+ may be new concepts for the treatment with NP-SLE.

AB - Systemic lupus erythematosus (SLE) is characterized by the presence of several autoantibodies, including anti-dsDNA. Among types of SLE, neuropsychiatric (NP)-SLE accounts for significant morbidity and mortality. Cerebrovascular disease, which could account for most of the serious permanent neurological damage, is a common presentation of NP-SLE. The pathophysiology of NP-SLE involves several factors, including vasculitis, thrombosis, and inflammation and/or apoptosis of neuronal and glial cells. The current treatment strategy is immunosuppressive therapy, which is occasionally insufficient for patients with NP-SLE. Recent studies have revealed that autoantibodies, such as anti-NR2, pass from the peripheral blood to the brain through the blood-brain barrier, cross-react with human brain tissue and cause increased intracellular Ca2+ in SLE. Regulating blood-brain barrier permeability, inhibiting autoantibody deposition in tissues and modulating intracellular Ca2+ may be new concepts for the treatment with NP-SLE.

KW - anti-NR2

KW - antiphospholipid

KW - antiribosomal P

KW - autoantibodies

KW - blood-brain barrier permeability

KW - cross-reactivity

KW - intracellular Ca signaling

KW - neuropsychiatric symptoms

KW - systemic lupus erythematosus

UR - http://www.scopus.com/inward/record.url?scp=84885576807&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84885576807&partnerID=8YFLogxK

U2 - 10.2217/ijr.13.48

DO - 10.2217/ijr.13.48

M3 - Review article

AN - SCOPUS:84885576807

VL - 8

SP - 585

EP - 595

JO - Future Rheumatology

JF - Future Rheumatology

SN - 1758-4272

IS - 5

ER -